Back to VRTX

VERTEX PHARMACEUTICALS INC / MA Deferred Revenue 2009-2017 | VRTX

Beta

What is deferred revenue?

Deferred revenue represents payments received in advance for goods or services that have not yet been delivered to customers.

What is VERTEX PHARMACEUTICALS INC / MA's current deferred revenue?

VERTEX PHARMACEUTICALS INC / MA (VRTX) annual deferred revenue for 2017 was $5.2M, a 13.92% decline from 2016. VERTEX PHARMACEUTICALS INC / MA deferred revenue for the quarter ending December 31, 2017 was $5.2M.

What was VERTEX PHARMACEUTICALS INC / MA's deferred revenue in 2016?

VERTEX PHARMACEUTICALS INC / MA annual deferred revenue for 2016 was $6.0M, a 63.15% decline from 2015.

What was VERTEX PHARMACEUTICALS INC / MA's deferred revenue in 2015?

VERTEX PHARMACEUTICALS INC / MA annual deferred revenue for 2015 was $16.3M, a 6.71% decline from 2014.

What is VERTEX PHARMACEUTICALS INC / MA's 5-year deferred revenue CAGR?

VERTEX PHARMACEUTICALS INC / MA deferred revenue grew at a compound annual growth rate (CAGR) of 28.45% from FY2012 to FY2017, going from $27.6M to $5.2M over 5 years.

Deferred Revenue History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Declining
CAGR-28.5%
FY2012
$27.6M
FY2017
$5.2M
091011121314151617
5 years selected
Deferred Revenue History
PeriodValueChangeSource
FY2017$5.2M-13.9%10-K
FY2016$6.0M-63.2%10-K
FY2015$16.3M-6.7%10-K
FY2014$17.5M-18.8%10-K
FY2013$21.5M-22.0%10-K
FY2012$27.6M-38.8%10-K
FY2011$45.0M-39.6%10-K
FY2010$74.6M-0.4%10-K
FY2009$75.0M-10-K
Company: VERTEX PHARMACEUTICALS INC / MATicker: VRTXSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →